Skip to main content
Year archive

Lineage Cell Therapeutics Inc. — 2021 filings

All 273 regulatory filings released by Lineage Cell Therapeutics Inc. (LCTX) in 2021, sourced directly from the official regulator.

273 Filings
2021 Period
2021 filings (273)
Filing Released Lang
Director's Dealing 2021
Director's Dealing
2021-12-30 English
Legal opinion relating to the ATM shares being offered in connection with the new ATM
Regulatory Filings
2021-12-21 English
Legal opinion relating to the ATM shares being offered in connection with the new ATM
Regulatory Filings
2021-12-21 English
PROSPECTUS SUPPLEMENT (To Prospectuses dated March 19, 2021 and May 8, 2020)
Capital/Financing Update
2021-12-21 English
PROSPECTUS SUPPLEMENT (To Prospectuses dated March 19, 2021 and May 8, 2020)
Capital/Financing Update
2021-12-21 English
Regulatory Filings 2021
Regulatory Filings
2021-12-21 English
Prospectus 2021
Prospectus
2021-12-21 English
ESTABLISHES EXCLUSIVE WORLDWIDE COLLABORATION WITH GENENTECH FOR THE DEVELOPMENT AND COMMERCIALIZATION OF OPREGEN® RPE CELL THERAPY FOR THE TREATMENT OF OCULAR DISORDERS
M&A Activity
2021-12-20 English
ESTABLISHES EXCLUSIVE WORLDWIDE COLLABORATION WITH GENENTECH FOR THE DEVELOPMENT AND COMMERCIALIZATION OF OPREGEN® RPE CELL THERAPY FOR THE TREATMENT OF OCULAR DISORDERS
Regulatory Filings
2021-12-20 English
Regulatory Filings 2021
Regulatory Filings
2021-12-20 English
6K-Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen
Regulatory Filings
2021-12-14 English
6K-Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen
Report Publication Announcement
2021-12-14 English
Regulatory Filings 2021
Regulatory Filings
2021-12-13 English
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
Earnings Release Q4 2021
2021-11-30 English
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
Report Publication Announcement
2021-11-30 English
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting
Earnings Release Q4 2021
2021-11-15 English
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting
Report Publication Announcement
2021-11-15 English
8K:THIRD QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS.
Earnings Release Q3 2021
2021-11-11 English
8K:THIRD QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS.
Report Publication Announcement Q3 2021
2021-11-11 English
FORM 10-Q For the quarterly period ended September 30, 2021
Interim / Quarterly Report Q3 2021
2021-11-11 English
FORM 10-Q For the quarterly period ended September 30, 2021
Report Publication Announcement
2021-11-11 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-11-10 English
Regulatory Filings 2021
Regulatory Filings
2021-11-10 English
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
Report Publication Announcement
2021-11-03 English
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
Report Publication Announcement
2021-11-03 English
OPREGEN® DATA UPDATE TO BE FEATURED AT 2021 AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
Regulatory Filings
2021-10-26 English
OPREGEN® DATA UPDATE TO BE FEATURED AT 2021 AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
Regulatory Filings
2021-10-26 English
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
Report Publication Announcement
2021-10-18 English
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
Report Publication Announcement
2021-10-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-10-13 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Major Shareholding Notification
2021-10-13 English
Director's Dealing 2021
Director's Dealing
2021-10-12 English
Regulatory Filings 2021
Regulatory Filings
2021-09-30 English
NEW OPREGEN® CLINICAL DATA FEATURED AT 54TH ANNUAL RETINA SOCIETY MEETING
Earnings Release Q3 2021
2021-09-30 English
NEW OPREGEN® CLINICAL DATA FEATURED AT 54TH ANNUAL RETINA SOCIETY MEETING
Report Publication Announcement
2021-09-30 English
FORM S-8 - 2021 Equity Incentive Plan
Share Issue/Capital Change
2021-09-29 English
FORM S-8 - 2021 Equity Incentive Plan
Report Publication Announcement
2021-09-29 English
Registration Form 2021
Registration Form
2021-09-28 English
LINEAGE TO PRESENT AT THE 2021 CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE ON SEPTEMBER 27, 2021
Regulatory Filings
2021-09-22 English
LINEAGE TO PRESENT AT THE 2021 CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE ON SEPTEMBER 27, 2021
Report Publication Announcement
2021-09-22 English
DATA FROM ONGOING CLINICAL TRIAL CONTINUES TO DEMONSTRATE A SINGLE ADMINISTRATION OF OPREGEN® CAN PROVIDE ANATOMICAL AND FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DRY AMD WITH GEOGRAPHIC ATROPHY
Earnings Release Q3 2021
2021-09-19 English
DATA FROM ONGOING CLINICAL TRIAL CONTINUES TO DEMONSTRATE A SINGLE ADMINISTRATION OF OPREGEN® CAN PROVIDE ANATOMICAL AND FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DRY AMD WITH GEOGRAPHIC ATROPHY
Report Publication Announcement
2021-09-19 English
Regulatory Filings 2021
Regulatory Filings
2021-09-15 English
OPREGEN® DATA UPDATE WILL BE FEATURED AT 54TH ANNUAL RETINA SOCIETY MEETING
Regulatory Filings
2021-09-13 English
OPREGEN® DATA UPDATE WILL BE FEATURED AT 54TH ANNUAL RETINA SOCIETY MEETING
Report Publication Announcement
2021-09-13 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-09-05 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Major Shareholding Notification
2021-09-05 English
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-09-05 English
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-09-05 English
Director's Dealing 2021
Director's Dealing
2021-09-02 English
Director's Dealing 2021
Director's Dealing
2021-09-02 English
SUPPLEMENTAL INFORMATION REGARDING PROPOSAL 4 – APPROVAL OF THE LINEAGE CELL THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN
Proxy Solicitation & Information Statement
2021-09-02 English
SUPPLEMENTAL INFORMATION REGARDING PROPOSAL 4 – APPROVAL OF THE LINEAGE CELL THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN
Remuneration Information
2021-09-02 English
Regulatory Filings 2021
Regulatory Filings
2021-09-02 English
LINEAGE ANNOUNCES APPOINTMENT OF GENERAL COUNSEL
Board/Management Information
2021-09-01 English
LINEAGE ANNOUNCES APPOINTMENT OF GENERAL COUNSEL
Report Publication Announcement
2021-09-01 English
FORM 10Q-financial results for the quarter ended June 30, 2021
Interim / Quarterly Report Q2 2021
2021-08-15 English
FORM 10Q-financial results for the quarter ended June 30, 2021
Report Publication Announcement Q2 2021
2021-08-15 English
financial results for the quarter ended June 30, 2021
Earnings Release Q2 2021
2021-08-15 English
financial results for the quarter ended June 30, 2021
Report Publication Announcement H1 2021
2021-08-15 English
The company's financial statements for the second quarter 2021 reported abroad
Regulatory Filings
2021-08-15 Hebrew (modern)
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-12 English
Regulatory Filings 2021
Regulatory Filings
2021-08-12 English
LINEAGE TO PRESENT AT THE H.C. WAINWRIGHT OPHTHALMOLOGY CONFERENCE ON AUGUST 17, 2021
Investor Presentation
2021-08-10 English
LINEAGE TO PRESENT AT THE H.C. WAINWRIGHT OPHTHALMOLOGY CONFERENCE ON AUGUST 17, 2021
Report Publication Announcement
2021-08-10 English
LINEAGE CELL THERAPEUTICS TO REPORT SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 12, 2021
Earnings Release Q2 2021
2021-08-05 English
LINEAGE CELL THERAPEUTICS TO REPORT SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 12, 2021
Report Publication Announcement
2021-08-05 English
INFORMATION REQUIRED IN PROXY STATEMENT
Proxy Solicitation & Information Statement
2021-08-04 English
INFORMATION REQUIRED IN PROXY STATEMENT
Proxy Solicitation & Information Statement
2021-08-04 English
Annual meeting of shareholders to be held September 13, 2021
Proxy Solicitation & Information Statement
2021-08-04 English
Annual meeting of shareholders to be held September 13, 2021
AGM Information
2021-08-04 English
Regulatory Filings 2021
Regulatory Filings
2021-08-03 English
Proxy Solicitation & Information Statement 2021
Proxy Solicitation & Information Statement
2021-08-03 English
Changes in Registrant’s Certifying Accountant
Regulatory Filings
2021-07-22 English
Changes in Registrant’s Certifying Accountant
Report Publication Announcement
2021-07-22 English
Regulatory Filings 2021
Regulatory Filings
2021-07-21 English
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy.
Earnings Release Q3 2021
2021-07-20 English
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy.
Report Publication Announcement
2021-07-20 English
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting.
Regulatory Filings
2021-07-13 English
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting.
Report Publication Announcement
2021-07-13 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Regulatory Filings
2021-07-04 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Major Shareholding Notification
2021-07-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FROM 4-Changes in Beneficial Ownership -Jayasuriya Anula
Director's Dealing
2021-07-04 English
FROM 4-Changes in Beneficial Ownership -Jayasuriya Anula
Report Publication Announcement
2021-07-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4-Changes in Beneficial Ownership - KINGSLEY ALFRED
Director's Dealing
2021-07-04 English
FORM 4-Changes in Beneficial Ownership - KINGSLEY ALFRED
Director's Dealing
2021-07-04 English
FORM 4-Changes in Beneficial Ownership - BRADSHER NEAL C.
Director's Dealing
2021-07-04 English
FORM 4-Changes in Beneficial Ownership - BRADSHER NEAL C.
Major Shareholding Notification
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Major Shareholding Notification
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-04 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-02 English
Director's Dealing 2021
Director's Dealing
2021-07-01 English
Director's Dealing 2021
Director's Dealing
2021-07-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-01 English
Statement of Changes in Beneficial Ownership - Russell Angus C
Director's Dealing
2021-07-01 English
Statement of Changes in Beneficial Ownership - Russell Angus C
Regulatory Filings
2021-07-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-07-01 English
Director's Dealing 2021
Director's Dealing
2021-07-01 English
Director's Dealing 2021
Director's Dealing
2021-07-01 English
Director's Dealing 2021
Director's Dealing
2021-07-01 English
The Company has been added to both the broad-market Russell 3000 Index as well as the Russell Microcap Index
Regulatory Filings
2021-06-28 English
The Company has been added to both the broad-market Russell 3000 Index as well as the Russell Microcap Index
Regulatory Filings
2021-06-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-06-27 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-06-27 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-06-27 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-06-27 English
Director's Dealing 2021
Director's Dealing
2021-06-25 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-06-24 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-06-24 English
Director's Dealing 2021
Director's Dealing
2021-06-23 English
OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
Regulatory Filings
2021-06-22 English
OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
Report Publication Announcement
2021-06-22 English
Director's Dealing 2021
Director's Dealing
2021-06-21 English
Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem
Regulatory Filings
2021-06-17 Hebrew (modern)
Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem
Regulatory Filings
2021-06-17 English
Regulatory Filings 2021
Regulatory Filings
2021-06-16 English
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
Regulatory Filings
2021-06-15 English
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
Report Publication Announcement
2021-06-15 English
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index.
Regulatory Filings
2021-06-09 English
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index.
Report Publication Announcement
2021-06-09 English
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen
Regulatory Filings
2021-06-03 English
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen
Report Publication Announcement
2021-06-03 English
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
Regulatory Filings
2021-06-01 English
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
Report Publication Announcement
2021-06-01 English
Regulatory Filings 2021
Regulatory Filings
2021-06-01 English
LINEAGE REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS SIGNIFICANT PROGRESS WITH ALL THREE CLINICAL PROGRAMS
Earnings Release Q1 2021
2021-05-18 English
LINEAGE REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS SIGNIFICANT PROGRESS WITH ALL THREE CLINICAL PROGRAMS
Report Publication Announcement
2021-05-18 English
report for the quarterly period ended March 31, 2021
Interim / Quarterly Report Q1 2021
2021-05-18 English
report for the quarterly period ended March 31, 2021
Report Publication Announcement Q1 2021
2021-05-18 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-13 English
Regulatory Filings 2021
Regulatory Filings
2021-05-13 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-09 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-09 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-09 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-09 English
Director's Dealing 2021
Director's Dealing
2021-05-06 English
Director's Dealing 2021
Director's Dealing
2021-05-06 English
Lineage increased the size of the Board to nine and appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., as a member of the Board to fill the newly created vacancy
Board/Management Information
2021-05-06 English
Lineage increased the size of the Board to nine and appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., as a member of the Board to fill the newly created vacancy
Board/Management Information
2021-05-06 English
Regulatory Filings 2021
Regulatory Filings
2021-05-05 English
Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors.
Board/Management Information
2021-05-05 English
Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors.
Board/Management Information
2021-05-05 English
Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
Report Publication Announcement
2021-05-04 English
Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
Report Publication Announcement
2021-05-04 English
Regulatory Filings 2021
Regulatory Filings
2021-05-03 English
Lineage announced today that updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research i
Earnings Release Q2 2021
2021-05-03 English
Lineage announced today that updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research i
Report Publication Announcement
2021-05-03 English
8k-Increased the size of the Board to eight and appointed Dr. Dipti Amin as a member of the Board
Board/Management Information
2021-04-25 English
8k-Increased the size of the Board to eight and appointed Dr. Dipti Amin as a member of the Board
Board/Management Information
2021-04-25 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-04-25 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-04-25 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-04-25 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Regulatory Filings
2021-04-25 English
Director's Dealing 2021
Director's Dealing
2021-04-22 English
Director's Dealing 2021
Director's Dealing
2021-04-22 English
Regulatory Filings 2021
Regulatory Filings
2021-04-22 English
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors.
Board/Management Information
2021-04-22 English
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors.
Board/Management Information
2021-04-22 English
Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform.
Regulatory Filings
2021-04-20 English
Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform.
Regulatory Filings
2021-04-20 English
OPREGEN® DATA UPDATE TO BE FEATURED AT 2021 ARVO ANNUAL MEETING.
Regulatory Filings
2021-04-12 English
OPREGEN® DATA UPDATE TO BE FEATURED AT 2021 ARVO ANNUAL MEETING.
Regulatory Filings
2021-04-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-04-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-04-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-04-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Major Shareholding Notification
2021-04-04 English
Director's Dealing 2021
Director's Dealing
2021-04-02 English
Director's Dealing 2021
Director's Dealing
2021-04-02 English
Entered into a Separation and Consulting Agreement
Board/Management Information
2021-03-30 English
Entered into a Separation and Consulting Agreement
Report Publication Announcement
2021-03-30 English
Regulatory Filings 2021
Regulatory Filings
2021-03-29 English
ANNOUNCES VITELLIFORM MACULOPATHY PATIENT TREATED WITH OPREGEN® UNDER NAMED PATIENT COMPASSIONATE USE
Regulatory Filings
2021-03-29 English
ANNOUNCES VITELLIFORM MACULOPATHY PATIENT TREATED WITH OPREGEN® UNDER NAMED PATIENT COMPASSIONATE USE
Report Publication Announcement
2021-03-29 English
Resignation of General Counsel and Corporate Secretary
Board/Management Information
2021-03-29 English
Resignation of General Counsel and Corporate Secretary
Board/Management Information
2021-03-29 English
Regulatory Filings 2021
Regulatory Filings
2021-03-26 English
8K-Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
Regulatory Filings
2021-03-24 English
8K-Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
Report Publication Announcement
2021-03-24 English
Regulatory Filings 2021
Regulatory Filings
2021-03-23 English
Regulatory Filings 2021
Regulatory Filings
2021-03-22 English
Regulatory Filings 2021
Regulatory Filings
2021-03-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2021-03-18 English
Director's Dealing 2021
Director's Dealing
2021-03-17 English
Director's Dealing 2021
Director's Dealing
2021-03-17 English
Director's Dealing 2021
Director's Dealing
2021-03-17 English
Regulatory Filings 2021
Regulatory Filings
2021-03-17 English
Regulatory Filings 2021
Regulatory Filings
2021-03-17 English
Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021
Regulatory Filings
2021-03-17 English
Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021
Report Publication Announcement
2021-03-17 English
SCHEDULE 13D/A24-Broadwood Partners, L.P
Major Shareholding Notification
2021-03-17 English
SCHEDULE 13D/A24-Broadwood Partners, L.P
Director's Dealing
2021-03-17 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-16 English
Regulatory Filings 2021
Regulatory Filings
2021-03-16 English
Regulatory Filings 2021
Regulatory Filings
2021-03-16 English
FORM S-3. REGISTRATION STATEMENT
Regulatory Filings
2021-03-13 English
FORM S-3. REGISTRATION STATEMENT
Regulatory Filings
2021-03-13 English
Securities offered to employees pursuant to employee benefit plans
Share Issue/Capital Change
2021-03-13 English
Securities offered to employees pursuant to employee benefit plans
Capital/Financing Update
2021-03-13 English
FORM F-3- REGISTRATION STATEMENT
Capital/Financing Update
2021-03-13 English
FORM F-3- REGISTRATION STATEMENT
Capital/Financing Update
2021-03-13 English
BUSINESS UPDATE
Earnings Release Q4 2020
2021-03-13 English
BUSINESS UPDATE
Report Publication Announcement
2021-03-13 English
10K - Annual Financial Report
Annual Report FY 2020
2021-03-13 English
10K - Annual Financial Report
Report Publication Announcement
2021-03-13 English
Registration Form 2021
Registration Form
2021-03-11 English
Registration Form 2021
Registration Form
2021-03-11 English
Registration Form 2021
Registration Form
2021-03-11 English
Annual Report 2020
Annual Report FY 2020
2021-03-11 English
Regulatory Filings 2021
Regulatory Filings
2021-03-11 English
RAISES $35.9 MILLION FROM SALES OF MARKETABLE SECURITIES HOLDINGS AND AN AT-THE-MARKET EQUITY OFFERING.
Capital/Financing Update
2021-03-08 English
RAISES $35.9 MILLION FROM SALES OF MARKETABLE SECURITIES HOLDINGS AND AN AT-THE-MARKET EQUITY OFFERING.
Share Issue/Capital Change
2021-03-08 English
Form of prospectus disclosing information. Prospectus Supplement.
Capital/Financing Update
2021-03-07 English
Form of prospectus disclosing information. Prospectus Supplement.
Report Publication Announcement
2021-03-07 English
8k- Recent Developments and Additional ATM Offering
Capital/Financing Update
2021-03-07 English
8k- Recent Developments and Additional ATM Offering
Report Publication Announcement
2021-03-07 English
Regulatory Filings 2021
Regulatory Filings
2021-03-05 English
Prospectus 2021
Prospectus
2021-03-05 English
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021.
Earnings Release Q4 2020
2021-03-01 English
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021.
Report Publication Announcement
2021-03-01 English
LINEAGE TO PRESENT AT THE RAYMOND JAMES 42ND ANNUAL INSTITUTIONAL INVESTORS CONFERENCE ON MARCH 1, 2021 AND THE H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE ON MARCH 9, 2021
Regulatory Filings
2021-02-23 English
LINEAGE TO PRESENT AT THE RAYMOND JAMES 42ND ANNUAL INSTITUTIONAL INVESTORS CONFERENCE ON MARCH 1, 2021 AND THE H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE ON MARCH 9, 2021
Report Publication Announcement
2021-02-23 English
FORM 4-Amended Statement of Changes in Beneficial Ownership
Director's Dealing
2021-02-17 English
FORM 4-Amended Statement of Changes in Beneficial Ownership
Major Shareholding Notification
2021-02-17 English
Director's Dealing 2021
Director's Dealing
2021-02-16 English
LINEAGE TO HOST VIRTUAL OPC1 INVESTOR & ANALYST DAY ON FEBRUARY 22, 2021
Report Publication Announcement
2021-02-16 English
LINEAGE TO HOST VIRTUAL OPC1 INVESTOR & ANALYST DAY ON FEBRUARY 22, 2021
Report Publication Announcement
2021-02-16 English
Annual filing director officer or owner of more than ten percent - Kingsley Alfred D.
Director's Dealing
2021-02-14 English
Annual filing director officer or owner of more than ten percent - Kingsley Alfred D.
Report Publication Announcement
2021-02-14 English
Director's Dealing 2021
Director's Dealing
2021-02-12 English
ENTERS INTO EXCLUSIVE AGREEMENT WITH NEURGAIN TECHNOLOGIES TO EVALUATE NOVEL DELIVERY SYSTEM FOR OPC1 TO TREAT SPINAL CORD INJURY
Regulatory Filings
2021-02-08 English
ENTERS INTO EXCLUSIVE AGREEMENT WITH NEURGAIN TECHNOLOGIES TO EVALUATE NOVEL DELIVERY SYSTEM FOR OPC1 TO TREAT SPINAL CORD INJURY
Report Publication Announcement
2021-02-08 English
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - Hernandez Alexandra.
Regulatory Filings
2021-01-24 English
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - Hernandez Alexandra.
Director's Dealing
2021-01-24 English
Director's Dealing 2021
Director's Dealing
2021-01-22 English
POSTS SERIES OF WEBINARS HIGHLIGHTING RECENT PROGRESS WITH ITS THREE CLINICAL-STAGE ALLOGENEIC CELL TRANSPLANT PROGRAMS
Investor Presentation
2021-01-21 English
POSTS SERIES OF WEBINARS HIGHLIGHTING RECENT PROGRESS WITH ITS THREE CLINICAL-STAGE ALLOGENEIC CELL TRANSPLANT PROGRAMS
Report Publication Announcement
2021-01-21 English
ANNOUNCES CHANGE TO EXECUTIVE TEAM
Regulatory Filings
2021-01-21 English
ANNOUNCES CHANGE TO EXECUTIVE TEAM
Report Publication Announcement
2021-01-21 English
ANNOUNCES CHANGE TO EXECUTIVE TEAM
Board/Management Information
2021-01-21 English
ANNOUNCES CHANGE TO EXECUTIVE TEAM
Board/Management Information
2021-01-21 English
Regulatory Filings 2021
Regulatory Filings
2021-01-20 English
SCHEDULE 13D-Lineage Cell Therapeutics, Inc. in ONCOCYTE CORPORATION
Major Shareholding Notification
2021-01-10 English
SCHEDULE 13D-Lineage Cell Therapeutics, Inc. in ONCOCYTE CORPORATION
Regulatory Filings
2021-01-10 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-01-08 English
Lineage will participate in virtual meetings with analysts and investors , Presentation
Investor Presentation
2021-01-06 English
Lineage will participate in virtual meetings with analysts and investors , Presentation
Report Publication Announcement
2021-01-06 English
Regulatory Filings 2021
Regulatory Filings
2021-01-06 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-CULLEY BRIAN M
Director's Dealing
2021-01-03 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-CULLEY BRIAN M
Director's Dealing
2021-01-03 English